Egypt’s Eva Pharma to provide India with 300,000 doses of COVID-19 drug remdesivir

Published: Updated:
Read Mode
100% Font Size
1 min read

Egypt’s Eva Pharma on Monday signed an agreement to provide India with 300,000 doses of remdesivir, used in the treatment of COVID-19, the company said in a statement.

The agreement, which was signed at the Indian embassy in Cairo, is aimed at helping India combat a surge in infections which has overwhelmed the health system and held close to record daily highs on Monday.

For more coronavirus news, visit our dedicated page.

Eva Pharma, a generic drugmaker established in 1997, said in June 2020 it had received a license from Gilead Sciences Inc to make remdesivir in Egypt and distribute it in 127 countries.

The drug targets moderate to severe cases of COVID-19 in intensive care who require oxygen.

Eva Pharma didn’t disclose the deal’s value.

Read more:

Dozens of suspected COVID-19 corpses wash up on banks of India’s Ganges river

India’s disaster hangs over countries facing rising COVID-19 infections

Egypt to test visitors from countries with COVID-19 variants on arrival

Top Content Trending